Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With:

  • Ximelagatran vs Warfarin: Is There a More Convenient Option for Anticoagulation in Atrial Fibrillation?

    New alternative anticoagulants now exist that may be equally efficacious as warfarin and allow a more convenient fixed dosing schedule with a superior safety profile.
  • Going to Pot with MS?

    In this randomized, placebo-controlled trial, 667 patients with stable advanced multiple sclerosis were assigned to 1 of 3 groups: oral cannabis, oral tetrahydrocannabinol, or placebo.
  • Best Office Test for Quadriceps Weakness

    Thirty-three consecutive patients with l3 or l4 radiculopathy were compared to 19 controls of comparable age to determine the best method for detecting quadriceps weakness in the office setting.
  • Market Updates

    The Centers for Medicare & Medicaid Services (CMS; Baltimore) recently asked the Heart Rhythm Society (HRS; Washington) to lead a working group to make recommendation for a national implantable cardioverter defibrillator (ICD) registry. Late in September, CMS posted a draft national coverage determination to expand coverage of ICDs.
  • Personnel File

    Adam Berman has been named vice president, research and development for MedicalCV (Minneapolis). He most recently was a regional sales manager for cardiac surgery-focused Coalescent Surgical. Medical CV is focused on developing products for improved patient outcomes by early treatment of cardiovascular disorders.
  • Product Pipeline

    SynCardia Systems (Tucson, Arizona), a developer of cardiac replacement and assist devices, in mid-October received final FDA approval for its CardioWest Temporary Total Artificial Heart (TAH-t) formerly the CardioWest Total Artificial Heart as a bridge to heart transplantation. Specifically, the approval is for use in cardiac transplant-eligible candidates at risk of imminent death from non-reversible biventricular failure.
  • Full November 1, 2004 Issue in PDF

  • Moving the Goalpost

    High-dose atorvastatin protects patients with acute coronary syndrome from death and major cardiovascular events better than usual dose pravastatin.
  • Diligent Dental Flossing May Help Prevent Stroke

    These data provide further support that inflammation in general and periodontal disease more specifically are stroke risk factors.
  • Pharmacology Update: Cinacalcet HCL (Sensipar) Tablets

    The first of a class of calcimimetics has been approved by the FDA for the treatment of hyperparathyroidism associated with renal failure and in patients with parathyroid cancer.